Surmodics, Inc. (SRDX)
After hours:
| Previous close | 34.55 |
| Open | 35.21 |
| Bid | 32.45 x 300 |
| Ask | 32.68 x 100 |
| Day's range | 32.33 - 35.21 |
| 52-week range | 16.79 - 39.41 |
| Volume | |
| Avg. volume | 72,187 |
| Market cap | 463.307M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | 33.84 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn., May 01, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024.
- Business Wire
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
EDEN PRAIRIE, Minn., April 19, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1.
- Business Wire
Surmodics to Participate in Upcoming Investor Conferences in March and April
EDEN PRAIRIE, Minn., February 27, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences:
